Status:
COMPLETED
Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Neutropenic Patients
Eligibility:
All Genders
14+ years
Phase:
NA
Brief Summary
The aim of the present work is to study the protein expressions profiles of neutropenic patients (with a high risk of invasive mycosis) who developed - versus who did not develop invasive mycosis (pri...
Eligibility Criteria
Inclusion
- \- Patients with malignant haemopathy who received chemotherapy likely to lead to severe neutropenia (PN\<500/mm3) for a foreseeable period of 10 days.
- Patients aged 14 years or older (no upper age limit)
- Patients with malignant haemopathy who received an autologous marrow graft.
- Patients with severe idiopathic medullar aplasia (PN\<500/mm3) who need to be hospitalised for at least 10 days consecutively (with or without immunosuppressant treatment).
- Patients who have provided written informed consent to participate in this study.
Exclusion
- Patients who received an allograft of marrow or hematopoietic stem cell transplant (given that these patients carry a risk of aspergillosis, which in most cases appears after medullar recovery, they will not be included in the study).
- Patients who received an autologous hematopoietic stem cell transplant (given that the duration of the neutropenia is often less than 10 days).
- Patients who do not meet the inclusion criteria
- Persons not covered by the national Health Insurance Agency
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01907477
Start Date
August 1 2008
End Date
November 1 2012
Last Update
July 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Dijon
Dijon, France, 21079